- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer | Clinical
Adagrasib Shows Efficacy and Tolerability in KRAS G12C–Mutated NSCLC
December 07, 2022
Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.
First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy
December 07, 2022
Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Interim Survival Analysis of Sitravatinib Allows for SAPPHIRE Study Continuation in NSCLC
December 06, 2022
An interim overall survival analysis of the novel therapy sitravatinib combined with nivolumab has cleared the way for a continuation of the phase 3 SAPPHIRE study in patients with advanced non-squamous non–small cell lung cancer.
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 05, 2022
During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
About the CANOPY-A Trial of Adjuvant Canakinumab in NSCLC
December 02, 2022
Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.
First- and Second-Line Treatment Options for Patients with mNSCLC and an EGFR Exon 20 Mutation
December 01, 2022
The panel reviews the first- and second-line treatment options for the patient in the presented case, before and after knowing her molecular testing results.
A Pathologist Outlines Typical Tumor Tissue Processing Steps after Biopsy in NSCLC
December 01, 2022
Michelle Shiller, DO, AP/CP, MGP, describes the process of tissue biopsy testing at her institution from start to finish, and Zosia Piotrowska, MD, explains the likelihood of targetable alterations in cases of mNSCLC in patients with no smoking history.
Domvanalimb Combinations Show Clinically Meaningful Efficacy in NSCLC
November 29, 2022
Clinically meaningful differentiation across efficacy measures were seen in patients administered domvanalimb in combination with zimberleimab or etrumadenant vs zimberelimab monotherapy.
Episode 11B: The Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
November 29, 2022
In this companion article, Dr Paul Bunn discuss the implications from the pooled results of trilaciclib on chemotherapy induced myelosuppression (CIM) and reviews management strategies for patients that might develop neutropenia while on chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
November 29, 2022
Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).